Update: Alector Shares Rise After Licensing AL050 Program to Roche's Genentech

MT newswire2026/10/05 19:04

03:04 PM EDT, 10/05/2026 (MT Newswires) -- (Updates with the latest stock movement in the first paragraph and headline.) Alector (ALEC) shares were up more than 18% in Monday trading after the company said it entered an exclusive global licensing agreement with Genentech, a Roche firm, for the development and commercialization of its AL050 program targeting Parkinson's disease. Under the deal, Alector said it will receive $100 million upfront and is eligible for up to $1.17 billion in development, regulatory and commercial milestones, as well as tiered royalties on net sales. Genentech will handle development, regulatory, manufacturing and commercialization globally, the company said. Alector said it will retain ownership of its antibody blood-brain-barrier transport platform and rights to use it across its wholly owned pipeline. Price: 2.14, Change: +0.33, Percent Change: +18.23

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

The value of cryptocurrency assets held by the U.S. government has shrunk by $16 billion from last year’s peak.

AiCoin•2026/10/11 03:23

Copper prices approach historic highs! UBS remains bullish: "Still most optimistic"

华尔街见闻•2026/10/11 01:57

A COVID Vaccine Stock on the S&P 500 Is Up 600% This Year

BeInCrypto•2026/10/10 22:48

The number of stablecoin holders on the Solana chain has surpassed 14 million.

AiCoin•2026/10/10 21:35